This trial is active, not recruiting.

Conditions radionuclide imaging (mibg scintigraphy), exercise test, blood pressure monitoring, ambulatory, sympathetic nerve activity, catecholamines
Treatment cpap
Phase phase 3
Sponsor University of Sao Paulo
Start date July 2010
End date July 2011
Trial size 20 participants
Trial identifier NCT01336335, Sympathetic activity and OSA


Recent evidences suggest that obstructive sleep apnea (OSA) can contribute to cardiovascular disease even in the absence of hypertension. However, there are few data regarding the impact of OSA on the sympathetic system in apparently normotensive patients with OSA as well as the impact of treatment with continuous positive airway pressure in different sites of activation (heart, peripheral nerves and circulating catecholamines)

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Intervention model parallel assignment
Masking open label
Primary purpose treatment
OSA treatment with CPAP
(No Intervention)
no intervention

Primary Outcomes

improvement in sympathetic activity in muscle sympathetic nerve activity (MSNA)
time frame: 3 months

Secondary Outcomes

improvement in sympathetic activity evaluated in different sites of activation
time frame: 3 months

Eligibility Criteria

Male participants from 30 years up to 60 years old.

Inclusion Criteria: - Severe OSA males Exclusion Criteria: - Smoking - Sustained Hypertension - Heart failure - Diabetes - Renal diseases - Under use of any medication - Under treatment for OSA

Additional Information

Official title The Effects of Continuous Positive Airway Pressure (CPAP) on Sympathetic Activity in Different Sites of Activation
Principal investigator Rodrigo Pedrosa, MD, PhD
Trial information was received from ClinicalTrials.gov and was last updated in April 2011.
Information provided to ClinicalTrials.gov by University of Sao Paulo.